Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials

Coronavirus disease-2019 (COVID-19) represents a global public health nightmare. The “cytokine storm,” the most prominent underlying pathophysiologic mechanism of this disease, can theoretically be targeted at several stages. Janus kinase (JAK) inhibitors constitute a drug class that could ameliorat...

Descripción completa

Detalles Bibliográficos
Autores principales: Patoulias, Dimitrios, Doumas, Michael, Papadopoulos, Christodoulos, Karagiannis, Asterios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384394/
https://www.ncbi.nlm.nih.gov/pubmed/34431004
http://dx.doi.org/10.1007/s10067-021-05884-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384394/
https://www.ncbi.nlm.nih.gov/pubmed/34431004
http://dx.doi.org/10.1007/s10067-021-05884-4

Ejemplares similares